Updated: Feb 15, 2022
EMPIRI's co-founder Dr. Kyuson Yun will be presenting at the AACR, mini-symposium session "Ex Vivo Models for Understanding Genetic Variation, Metastasis, and Treatment Sensitivity" on our platform technology, "E-slice: A novel 3D culture platform for precision medicine". #medicine #technology #culture #precisionmedicine #precisiononcology #cancerdiagnostics #aacr #drugdevelopment #drugdiscovery #pharmaceutical
EMPIRI's E-slice 3D tumor culture platform for real-time evaluation of therapeutic candidates can now be accessed through our store-front at Scienist.Com for expedited study quoting and contracting.
Funding to support a cancer diagnostic system to measure empirical treatment response Houston, TX, July 20, 2023 - EMPIRI, Inc., who is revolutionizing how we treat cancer by providing empirical, pers
San Francisco, CA, Jan 8, 2023– EMPIRI today announced that it is presenting at Biotech Showcase™ 2023. This year, registered attendees can view EMPIRI’s presentation live, and also access a recorded